Journal Watch · Drug Discovery Today · 2026
Addressing delivery and resistance issues of CDK4/6 inhibitors as cancer therapeutics.
Overall, these novel formulation strategies represent a promising frontier for improving the clinical potential of CDK4/6 inhibitor therapy.
TL;DR
Overall, these novel formulation strategies represent a promising frontier for improving the clinical potential of CDK4/6 inhibitor therapy.
Key findings
- Overall, these novel formulation strategies represent a promising frontier for improving the clinical potential of CDK4/6 inhibitor therapy.
What they did
However, the high dose, frequent administration, and acquired resistance of these newer anti-cancer molecules significantly limits their therapeutic application. In this review, we explore the current landscape of nanoformulations and advanced formulation strategies, including lipid and polymeric-based systems, salt forms, and inclusion complexes, for improving the efficacy of CDK4/6 inhibitors and circumventing resistance mechanisms.
Full abstract (original)
Background: Cancer treatment is limited by poor specificity, efficacy, toxicity and resistance associated with conventional treatment options involving surgery, chemotherapy, and radiation therapy. The introduction of newer targeted agents, such as cyclin-dependent kinases-4 and -6 (CDK4/6) inhibitors, in the treatment of hormone receptor-positive breast cancer has improved breast cancer treatment.
What they did: However, the high dose, frequent administration, and acquired resistance of these newer anti-cancer molecules significantly limits their therapeutic application. In this review, we explore the current landscape of nanoformulations and advanced formulation strategies, including lipid and polymeric-based systems, salt forms, and inclusion complexes, for improving the efficacy of CDK4/6 inhibitors and circumventing resistance mechanisms.
Results & conclusions: Overall, these novel formulation strategies represent a promising frontier for improving the clinical potential of CDK4/6 inhibitor therapy.
Abstract © the authors / Drug Discovery Today (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.drudis.2026.104663 · PubMed 41951034.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Drug Discovery Today study find?
Overall, these novel formulation strategies represent a promising frontier for improving the clinical potential of CDK4/6 inhibitor therapy.
What type of study is this?
It is a review / perspective, published in Drug Discovery Today in 2026. However, the high dose, frequent administration, and acquired resistance of these newer anti-cancer molecules significantly limits their therapeutic application.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.drudis.2026.104663. PubMed ID: 41951034. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/addressing-delivery-and-resistance-issues-of-cdk4-6-inhibitors-as-cancer-104663/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides